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INTRODUCTION 
According to the World Health Organization (WHO) data in 2017, it 
is estimated that more than 2 billion people are infected with the 
Hepatitis B Virus (HBV) around the world and 257 million people 
have chronic HBV infection. Most of the 887,000 deaths resulting 
from hepatitis B infection in 2015 were due to complications such 
as cirrhosis and hepatocellular carcinoma (HCC) (1).
HBV infection is usually acquired in adulthood. Transmission 
through sexual contact and parenteral drug use with shared 
needles in adolescents and young adulthood has been identified 
as the most important transmission route. However, perinatal 
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Aim: In this study, we randomized the patients without known hepatitis-B, hepatitis C and HIV infection who presented to the emergency 
department (ED). We measured the serum levels of HBsAg, Anti-HCV and Anti-HIV antibodies besides biochemical tests regarding the 
diagnostic process of the main complaint resulting in presentation to the ED. In this way, we aimed to determine the prevalence of occult 
chronic viral diseases among patients presenting to the ED and the risk of ED employees was evaluated.
Materials and Methods: The study included 800 patients who had presented to the ED for any reason over two month and who had no 
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Results: Four hundred and thirthy-four (54.2%) of the patients were male, 366 (45.8%) were female, and the mean age was 32.7 (±16.9) 
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0.0%, respectively.
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or early childhood infections also pose a great risk for the 
development of HBV infection (2). Many epidemiological and 
molecular studies have shown that chronic HBV infection is 
the main risk factor for the development of HCC. Chronic HBV 
infection is seen in approximately 5% of infections seen in adults, 
whereas, this rate accounts for 90% in neonatal infections. 
Although HBV generally does not cause direct cytopathic effects 
in hepatocytes, it is thought to induce hepatic damage (fibrosis, 
cirrhosis, and HCC) as a result of persistent immune reaction and 
inflammation in the liver (3). The European Center for Disease 
Prevention and Control has reported the prevalence of HBV 
infection among the general population in Turkey as 2-8% by 
September 2010 (4).
Hepatitis C Virus (HCV) spreads predominantly through blood 
and blood contamination, such as drug injection. Furthermore, 
HCV outbreaks have been linked to non-sterile medical practices, 
unprotected blood transfusions and sexual transmission (5-9). 
Around two hundred million people (3% of the whole population) 
are infected with HCV worldwide. Approximately three to four 
million new cases are seen each year, and more than 350,000 
people die each year due to diseases caused by HCV infection. 
There is very little data about the genetic properties and regional 
distribution of HCV infection in Turkey (7).
According to the 2018 data of the United Nations AIDS Unit, it 
is reported that approximately 36.9 million people are infected 
with Human Immunodeficiency Virus (HIV) worldwide and 53.1% 
(19.6 million) of them live in sub-Saharan Africa. As of 2017, the 
number of people receiving antiretroviral treatment reached 19 
million and the mortality rate decreased by 34%. According to 
the 2016 data in our country, a total of 14695 HIV infected/AIDS 
cases were reported (10,11).
Previous studies have shown that the rate of contact of emergency 
service providers with the blood, blood products and body fluids 
of patients admitted to the emergency department is rather 
high. Similarly, the incidence of occupational exposure to blood 
or other body fluids is higher among Emergency Department (ED) 
workers than in the general public officials (12-16). This situation 
increases the risk of transmission of HBV, HCV and HIV infection 
among health care providers in ED. In this study, we aimed to 
conduct a risk analysis for ED health workers due to the patients 
who presented to the ED without a history of HBV, HCV or HIV 
infection. 
Materials and Methods
The study was approved by the Gaziantep University Faculty 
of Medicine Ethics Committee for Clinical Studies (approval 
date: 12.09.2018, decision no: 2018/211) and carried out in 
the Department of Emergency Medicine at Şahinbey Research 
and Practice Hospital. The study was conducted following the 
Declaration of Helsinki and an informed consent form was signed 
by each participant before blood samples were drawn. Health 
care is provided to approximately 180,000-210,000 patients 
annually in the afore-mentioned ED. A total of 44,720 patients 
had presented to our ED during the two months of the study.
A total of 800 patients who had presented to the Adult ED with 
any complaint between 01.10.2018 and 01.12.2018 and who 
fulfilled the study criteria were randomly recruited. To provide 
randomization in the study, the resident on duty included the 
first patient who presented at his/her shift every hour and who 
fulfilled the study criteria and gave written consent.
Pre-prepared forms for the study included the patients’ age, 
gender, medical history, history of regular drug use, surgical 
interventions (including curettage and superficial abscess 
drainage), alcohol or drug/stimulant use, blood replacement 
history, presence of individuals with infectious viral diseases 
(HBV, HCV, HIV) in their domestic environment, and the HBV 
vaccination history was recorded.
The exclusion criteria; patients with a history of HBV, HCV or HIV 
infection, those younger than 16 years, and those who refused to 
participate voluntarily were excluded from the study.
The inclusion criteria and workflow; Patients older than 16 years 
of age presenting to our ED for any reason at any time of the day 
and who did not know whether or not they were infected with 
HBV, HCV or HIV were included in the study. In addition to the 
laboratory samples examined in the diagnostic process of patients 
who fulfilled the study criteria, 3 ccs of extra blood samples were 
collected for the measurement of serum HBsAg, anti-HCV and anti-
HIV antibody levels and sent to the Microbiology Laboratory of 
Şahinbey Research and Practice Hospital. The blood samples were 
transferred to the BD Vacutainer® SSTTM II Advance (REF 367955) 
biochemistry tubes containing gel and taken to the laboratory 
within 5 minutes. The samples were recorded in the medical 
automation system and centrifuged in the laboratory at 4000 rpm 
for 5 minutes. The serum on top of the precipitate was removed and 
examined using the Abbott® kits on the Architect 2000 SR® (ELISA) 
device. Blood samples that were not examined immediately were 
separated by centrifugation and stored at -20 oC for a maximum 
of 2 days and then examined in the same way. The device used for 
analysis works according to the Macro ELIZA principle.
The number of samples was calculated by considering the study 
with the highest rate (8%) in our country and WHO data averages 
(3%) (3). We use the internationally recognized formula in the 
calculation as follows:
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N1= {z1 – α/2 ±    p- * q * (1+ 1)+z1 –  ×     p1 * q1 + (p2+q2)}2/ 2
(17)
Based on the assumption that the study was in the 85% confidence 
interval when the values were used in this formulation,
N1 = 372, N
2
 = k x N
1
 = 372, Total n=744 number of participants 
(sample size) was calculated. Thus, we recruited a total of 800 
subjects.
Statistical Analysis
The data of the patients were recorded at a computer file and 
analyzed with the SPSS 23.0 program. A chi-square test was used 
to analyze the relationship between two categorical variables; 
the t-test was used to compare the dependent variables. A p 
value of less than 0.05 was considered statistically significant.
Results
Of the 44,720 patients presenting to our emergency department 
during the two-month study period, 21,500 (48.08%) were 
male and 23,320 (51.92%) were female and the mean age was 
34.74±16.80 years. Of the 800 patients who were recruited in the 
study, 434 (54.2%) were male, 366 (45.2%) were female and the 
mean age was 37.7±16.8 years. 58.4% of the patients were within 
the 16-35 age category (Table 1).
Among eight hundred patients, incidental HBV-positivity and 
HCV-positivity were 16 (2%) and six (0.8%), respectively. None of 
the patients had HBV and HCV coexistence. No incidental HIV-
positive patients were determined. HBV-positivity was dominant 
in females and HCV-positivity in males (Table 2).
Of the patients included in the study, 23.3% (186) reported having 
a chronic disease. Among these 186 patients, HBV-positivity was 
determined in six (3.2%) and HCV-positivity in one (0.5%). There 
was no statistically significant relationship between the presence 
of chronic disease and HBV-positivity (p=0.173) or HCV-positivity 
(p=0.702) (Table 3).
Of 175 patients (21.9%) who reported chronic drug use, six 
(3.4%) had HBV-positivity and one (0.6%) had HCV-positivity. 
The relationship between chronic drug use and HBV-positivity 
(p=0.127) or HCV-positivity (p=0.757) was not statistically 
significant (Table 3).
One hundred and thirthy patients (16.3%) stated that they had 
undergone a surgical operation previously. HBV was positive in 
three (2.3%) and HCV was positive in one (0.8%) of them. There 
was no statistically significant relationship between a previous 
surgical operation history and HBV-positivity (p=0.784) or HCV-
positivity (p=0.978) (Table 3).
None of the patients reported chronic alcohol or stimulant/drug 
use. However, 8% (n=64) of the participants defined themselves 
as “social drinkers”. HBV-positivity (p=0.794) was found in one 
(1.6%) and HCV-positivity (p=0.022) in two (3.1%) of 64 patients 
who stated that they were social drinkers (Table 3).
Forty-five (5.6%) patients reported that they had previously 
undergone blood transfusion for any reason. HBV-positivity was 
found in one (2.2%) (p=0.913) and HCV-positivity was found in 
two (4.4%) (p=0.003) of these 45 patients (Table 3).
When we questioned the presence of an individual with the 
infectious viral disease in his/her domestic environment, eight 
(1%) subjects reported that there was an HBV-positive person at 
home. One of these eight (12.5%) was HBV-positive (p=0.160). 
Four (0.5%) subjects reported that there was an HCV-positive 
person at home. HCV was positive in one of these four (25%) 
(p=0.001) (Table 3). None of the participants reported that there 
was an HIV-positive person at home. 
A total of 124 subjects (15.5%) declared that they had been 
vaccinated against HBV. Sixty-one (7.6%) of them were male 
and 63 (7.9%) were female. There were no patients among those 
undergoing HBV vaccination, who had a concomitant HBV 
infection. 
Table 1. Age Groups and gender distribution of patients
Age category, (year) Male Female Total, n (%)
16-25 109 110 219 (27.5%)
26-35 142 106 248 (30.9%)
36-45 73 58 131 (16.4%)
46-55 35 32 67 (8.3%)
56-65 27 21 48 (6.0%)
+66 48 39 87 (10.9%)
Total 434 (54.2%) 366 (45.8%) 800 (100%)
Table 2. Presence of HBV and HCV infection and gender 
distribution of patients
Male Female Total
HBV Positive (+) 7 9 16
Negative (-) 427 357 784
Total 434 366 800
HCV Positive (+) 4 2 6
Negative (-) 430 364 794
Total 434 366 800
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It is reasonable to say that studies conducted in emergency 
services in our country can be considered as an indicator of the 
general prevalence of the population in epidemiological studies 
due to the high number of participants.
HBV infection shows significant racial/ethnic and geographic 
differences regarding viral exposure and immunity. In the United 
States, the overall prevalence of chronic HBV infection in the 
general population is 0.34%, which is more common among 
Asians and the black population (17). The European continent is 
a low endemic region for HBV infection. The overall prevalence 
of HBV is about 0.9% in EU countries. The number of cases with 
chronic HBV infection is estimated to be approximately 4.7 million 
in Europe (18). Chronic HBV infection is thought to be highly 
endemic in the overall African continent. In Asia, both high and 
low-risk countries have been reported regarding HBV infection. 
The rate of the population with chronic HBV infection has been 
reported to be 2-4% in Japan, 5-18% in China, 15-20% in Taiwan, 
and 2-7% in Iran (19-22). The prevalence of chronic HBV infection 
was found as 4-5% in Turkey in 2007 and it was reported to be 
4.57% in a meta-analysis published in 2011 (23-24). Similarly, 
HBV-positivity was calculated as 4% in another study population 
by Tozun et al. (25). In our study, the incidental HBV-positivity 
prevalence was calculated as 2% (16 patients). When the results 
of our study were compared with previous studies in our country, 
a lower prevalence rate was found. We believe that the success of 
routine HBV vaccination, which was launched in 1998 in Turkey, 
has a great contribution to this decline. Similarly, in Taiwan (26), 
China (27) and Poland (28), the incidence of HBsAg-positivity has 
been shown to decrease after initiation of routine nationwide 
HBV vaccination program. We believe that the inclusion of the 
HBV vaccine in the routine vaccination programs is an important 
factor in decreasing the prevalence of HBV worldwide.
Studies reporting the prevalence of HCV have demonstrated 
significant geographical and regional differences in the 
epidemiology of HCV infection in Europe. In general, the 
prevalence of HCV is between 0.1-1% in northern Europe, 0.2-1.2% 
in Central Europe and 2.5-3.5% in southern Europe (29). Among 
the continents, the estimated prevalence is lowest in Northern 
Europe where the prevalence of HCV was reported to be lower 
than 1%; its prevalence is high in countries in North Asia and 
Africa. The lowest HCV prevalence was reported in the UK and 
the Scandinavian countries (less than 1%); the highest prevalence 
was reported from Egypt (15-20%) (30,31). In our country, the 
epidemiological data for HCV are mostly obtained from local 
studies, and anti-HCV positivity has been reported between 0.1-
1.5% in community-based studies (23,32,33). The best estimate 
of the prevalence of HCV in our country is approximately 1% 
(33). In our study, the rate of anti-HCV-positive patients was 0.8%. 
Our results are consistent with other studies conducted in our 
country.
The HIV prevalence in Turkey was found to be 0.019% in 2016 
(10). However, there were no HIV-positive patients determined in 
our study. Due to the extremely low incidence and the relatively 
small sample size of our study, the absence of HIV-positive 
patients was considered to be normal in our results. 
Of the 45 patients (5.6%) who declared that they had received 
blood transfusion for any reason in our study, one (2.2%) had 
HBV-positivity (p=0.913) and two (4.4%) had HCV-positivity 
(p=0.003). Blood transfusion is an important route of viral 
transmission in developing countries. In developed countries, 
transmission through blood transfusions has decreased 
considerably. For example, the risk of HCV transmission is 
estimated to be approximately 0.52 per million donations in 
the US, 0.70 in Canada, and between 0.1 and 2.33 in different 
European countries (33-35). According to our results, HCV 
transmission among patients receiving blood transfusion is quite 
high compared to the rates in developed countries. However, in 
our study, it is not possible to attribute the cause of transmission 
to blood transfusion alone in these patients. In our study, two 
(33%) of six HCV positive patients were over 50 years of age. In 
the literature, some studies show the relationship between HCV 
positivity and the patient’s age. However, we did not reach such 
Table 3. The Relationship between HBV/HCV positivity and patient characteristics
Total patients HBV + p value HCV + p value
Presence of chronic illness 186 6 0.173 1 0.702
Regular drug intake 175 6 0.127 1 0.757
Past surgery history 130 3 0.784 1 0.978
Alcohol intake 64 1 0.794 2 0.022*
Blood transfusion history 45 1 0.913 2 0.003*
Presence of a virally infected person in the domestic environment 64 1 0.160 2 0.001*
HBV: Hepatitis B Virus, HCV: Hepatitis C Virus, *Significant at p<0.05 level (p values were obtained by chi-spuare test)
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a conclusion in our study. In a study conducted by Niu et al. 
(34) on 2685 patients in China, the distribution of patients was 
examined by age and the rate of those older than 50 years was 
found to be 59.33%. In our country, some studies are examining 
the age-specific prevalence of HCV showing that the prevalence 
of HCV increases with age, especially after the age of 50 years 
(25,30). The results of our study were not consistent with the 
afore-mentioned studies in the literature in terms of age and 
HCV-positivity. In our study, the number of patients with HCV 
was only six, which did not allow the comparison of the HCV 
prevalence under and above 50 years of age.
In our study, the relationship between the presence of an HCV-
positive person at home and HCV-positivity was statistically 
significant. Some studies in the literature have reported similar 
results. Anti-HCV-positivity was determined in 20.5% of people 
living with an HCV-positive person at home in a study evaluating 
domestic HCV transmission in Pakistan, while another study in 
Egypt reported 18% anti-HCV-positivity (36-38). In our study, four 
(0.5%) subjects declared to live with an HCV-positive individual 
at home. HCV-positivity was determined in one (25%) of these 
four people. Our result was statistically significant [(p=0.001) 
(Table 3)] and supports previous studies. In particular, educating 
people living with HBV, HCV and HIV-positive individuals at their 
homes regarding the transmission routes of the disease would be 
effective in reducing the transmission rates.
Study Limitations
As the sociocultural structure of our society is taken into 
consideration, it is highly likely to provide incomplete or 
misleading information on alcohol and drug/substance use, 
since only the patients’ declaration was based in our study. For 
the same reason, although suspicious sexual intercourse is an 
important route of transmission, which can explain unknown 
reasons, the fact that it could not be questioned has created 
a significant limitation in our study. Since there were no HIV-
positive patients in our study, no detailed analysis could be 
performed.
Conclusion
Emergency departments are units to which a large number of and 
all kinds of patients present and the necessary interventions are 
required without waiting for the results of biochemical analyses. 
Emergency Medicine Specialists and other ED employees are 
at high risk of exposure to blood-borne pathogens in these 
intensive settings. Although the incidence of HBV/HCV/HIV 
infection appears to be low in our study, health workers should 
comply fully with personal protection methods due to the high 
risk of transmission.
In our study, the rate of those who declared the presence of 
HBV vaccination was found to be 15.5% among 800 patients. 
Increasing the vaccination rates and performing them properly 
will decrease the prevalence of HBV infection to lower rates in 
our country.
The lack of a significant decrease in the prevalence of HCV in 
our country over the years reveals the importance of vaccination 
development studies. The lack of an effective vaccine yet can 
be seen as one of the main reasons why the desired success in 
combating the disease has not been achieved. However, it is 
possible to decrease the rate of transmission by increasing social 
awareness. 
We believe that the publication of a large number of news and 
visual materials in the media regarding HIV infection results 
in a high level of awareness of the disease in our country. The 
registration and follow-up of the digital medical file system by 
the Ministry of Health is quite successful for HIV infection and 
AIDS. Although the number of patients is low in our country, it 
is very important for public health that the fight against HIV is 
not interrupted.
Ethics 
Ethics Committee Approval: Ethics committee approval was 
taken from Gaziantep University Faculty of Medicine Ethics 
Committee for Clinical Studies (approval date: 12.09.2018, 
decision no: 2018/211).
Informed Consent: Informed consent forms were signed by each 
participant before blood samples were drawn.
Peer-review: Externally and internally peer-reviewed.
Authorship Contributions
Concept: B.A., Y.Z., Design: B.A., M.M.O., Data Collection or 
Processing: C.K., H.G., M.M.O., M.S. Analysis or Interpretation: B.A., 
Y.Z., Literature Search: M.M.O., M.S., Writing: M.M.O., M.S., M.B.
Conflict of Interest: The authors declared no potential conflicts 
of interest with respect to the research, authorship, and/or 
publication of this article.
Financial Disclosure: The authors received no financial support 
for the research, authorship, and/or publication of this article.
References
1.  World Health Organization Progress Reports 2018 http://www.who.int/
mediacentre/factsheets/fs204/en/ (Accessed: 06/04/2019).
2.  Alabaz D. Çocuklarda Kronik Hepatit B Tedavisi. Alhan E (Editör). Çocukluk 
Çağında Viral Hepatitler. İstanbul; Medya Tower Tanıtım ve Yayıncılık, 2007. 
p45-50. 
3.  Schuppan D, Afdhal NH. Liver cirrhosis. The Lancet; 2008;371:838-51.
4.  European Centre for Disease Prevention and Control. Systematic review on 
hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.
Oktay et al. Viral marker in the Emergency Department
Eurasian J Emerg Med. 
2020;19(2): 105-10
110
5.  Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SY, Shapiro B, Pybus OG, et 
al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and 
phylogeographic analysis. PLoS medicine. 2009;6:e1000198.
6.  Sunbul M, Khan A, Kurbanov F, Leblebicioglu H, Sugiyama M, Tanaka Y, et 
al. Tracing the spread of hepatitis C virus in Turkey: a phylogenetic analysis. 
Intervirology. 2013;56:201-5.
7.  Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and 
HIV infections among blood donors in Izmir, Turkey. Indian journal of 
medical microbiology. 2008;26:288.
8.  Lampe E, Espirito-Santo MP, Martins RM, Bello G. Epidemic history of 
Hepatitis C virus in Brazil. Infection, Genetics and Evolution. 2010;10:886-95.
9.  Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV 
infection. Nature reviews Gastroenterology & hepatology. 2013;10:553.
10.  WHO Global HIV Report 2016. https://www.who.int/hiv/pub/arv/global-aids-
update-2016-pub/en/ (Accessed: 06/04/2019).
11.  Tümer A. HIV/AIDS nedir? (2019). http://www.hatam.hacettepe.edu.tr/AIDS_
web-2019.pdf (Accessed: 06/04/2019).
12.  Van Wijk PT, Pelk-Jorgen M, De Boer E, Voss A, Wijkmans C, Schneeberger 
PM. Differences between hospital-and community-acquired blood exposure 
incidents revealed by a regional expert counseling center. Infection. 
2006;34:17-21.
13.  Averhoff FM, Moyer LA, Woodruff BA, Deladisma AM, Nunnery J, Alter MJ, et 
al. Occupational exposures and risk of hepatitis virus infection among public 
safety workers. J Occup Environ Med. 2002;44:591-6.
14.  Gershon RMR, Sherman M, Mitchell C, Vlahov D, Erwin MJ, Lears MK, et 
al. Prevalence and risk factors for bloodborne exposure and infection in 
correctional healthcare workers. Infect Control Hosp Epidemiol. 2007;28:24-
30.
15.  Lorentz J, Hill L, Samimi B. Occupational needlestick injuries in a metropolitan 
police force. Am J Prevent Med. 2000;18:146-50.
16.  Pagane J, Chanmugam A, Kirsch T, Kelen GD. New York City Police Officers 
incidence of transcutaneous exposures. Occup Med (Lond). 1996; 46:285-8.
17.  Rosner B. Fundamentals of Biostatistics. 7th ed. Boston, MA: Brooks/Cole; 
2011.
18.  Kim HS, Rotundo L, Yang JD, Kim D, Kothari N, Feurdean M, et al. Racial/
ethnic disparities in the prevalence and awareness of Hepatitis B virus 
infection and immunity in the United States. Journal of viral hepatitis. 2017; 
24:1052-66.
19.  Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et 
al. Hepatitis B virus burden in developing countries. World journal of 
gastroenterology. 2015;21:11941. 
20.  Tun W, Vu L, Adebajo SB, Abiodun L, Sheehy M, Karlyn A, et al. Population-
based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and 
chlamydia in male injection drug users in Lagos, Nigeria. International 
journal of STD & AIDS. 2013;24:619-25. 
21.  Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the 
Asia–Pacific region. Journal of gastroenterology and hepatology. 2000;15:E3-
E6.
22.  Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: 
a review article. Journal of research in medical sciences: the official journal 
of Isfahan University of Medical Sciences. 2009;14:249.
23. Mıstık R. The epidemiology of viral hepatitis in Turkey. Analysis of published 
data. Viral hepatitis. Ankara: Association of Viral Hepatitis. 2007;18:10-50.
24.  Toy M. Age- and region-specific hepatitis B prevalence in Turkey estimated 
using generalized linear mixed models: a systematic review. BMC Infectious 
Diseases. 2011;11:1 
25.  Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. 
Seroprevalence of hepatitis B and C virus infections and risk factors in 
Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection. 
2015;21:1020-6
26.  Ni YH, Chang MH, Huang LM. Hepatitis B Virus Infection in Children and 
Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B 
Vaccination. Annals Internal Medicine. 2001;135:796-800.
27.  Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy 
on hepatitis B virus infections in China over a 20-year period. International 
Journal of Infectious Disaeses. 2012;16:82-8.
28.  Magdzik W. Hepatitis B epidemiology in Poland, Central and Eastern Europe 
and the newly independent states. Vaccine. 2000;18:13-6.
29.  Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus 
infection in Europe. J Hepatol. 2008;48:148-62.
30.  Bahap M. Hepatit B ve C Virüsü ile Enfekte Hastaların Tedavisinde İlaç Kaynaklı 
Sorunlar (Master’s thesis, Sağlık Bilimleri Enstitüsü). Ankara; Hacattepe 
University. 2018. http://www.openaccess.hacettepe.edu.tr:8080/xmlui/
bitstream/handle/11655/4802/10209106.pdf?sequence=1&isAllowed=y
31.  Kayman T, Karakükçü Ç, Karaman A, Gözütok F. Kayseri bölgesinde Hepatit 
C virüs enfeksiyonunun genotip dağılımı. Türk Mikrobiyol Cem Derg. 
2012;42:21-6.
32.  Dursun M, Ozekinci T, Ertem M, Saka G, Yilmaz S, Canoruc F, et al. Prevalence 
of hepatitis C in adults in the south-eastern region of Anatolia: a community-
based study. Hepatol Res. 2004;29:75-80.
33.  Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus 
seroprevalence in rural areas of the South-western region of Turkey. Int J 
Infect Dis. 2009;13:274-84.
34.  Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus 
prevalence and genotypes of individuals of physical examination in WuHan, 
Central China. Springerplus. 2016;5:1557.
35.  Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. 
Liver International. 2004;24:519-25.
36.  Shadid I. Hepatitis C Virus Infection Treatment: Recent Advances and New 
Paradigms in the Treatment Strategies. 2017;285-308.
37.  Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus 
infection therapy. The Journal of infectious diseases. 2013;207:S33-S9.
38.  Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis 
of hepatitis C virus genotypes and subtypes based on the complete coding 
region. Liver international. 2012;32:339-45.
